Doctors in India raise concerns about new mandate to prescribe generically or risk suspension
BMJ 2023; 382 doi: https://doi.org/10.1136/bmj.p1930 (Published 22 August 2023) Cite this as: BMJ 2023;382:p1930- Shefali Malhotra
- New Delhi
Doctors in India have raised concerns about a new rule, which came into effect on 2 August, that requires them to prescribe drugs using generic names and avoid referring to specific brands.
The Indian Medical Association said that the regulation was “a matter of great concern since it directly impacts patients’ care and safety.” It has asked that it be deferred until the government can assure the quality of all drugs manufactured in India.
The directive from the National Medical Commission, which regulates doctors in India, said that failure to comply with the rule could lead to a doctor’s licence being suspended for up to a month.1
The commission said that generic drugs are 30-80% cheaper than branded drugs …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.